| Autor: |
Philip M, Bath, Cameron J C, Skinner, Charlotte S, Bath, Lisa J, Woodhouse, Anastasia Areti Kyriazopoulou, Korovesi, Hongjiang, Long, Diane, Havard, Christopher M, Coleman, Timothy J, England, Valerie, Leyland, Wei Shen, Lim, Alan A, Montgomery, Simon, Royal, Amanda, Avery, Andrew J, Webb, Adam L, Gordon |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
European geriatric medicine. 13(6) |
| ISSN: |
1878-7649 |
| Popis: |
Purpose Infections cause considerable care home morbidity and mortality. Nitric oxide (NO) has broad-spectrum anti-viral, bacterial and yeast activity in vitro. We assessed the feasibility of supplementing dietary nitrate (NO substrate) intake in care home residents. Methods We performed a cluster-randomised placebo-controlled trial in UK residential and nursing care home residents and compared nitrate containing (400 mg) versus free (0 mg daily) beetroot juice given for 60 days. Outcomes comprised feasibility of recruitment, adherence, salivary and urinary nitrate, and ordinal infection/clinical events. Results Of 30 targeted care homes in late 2020, 16 expressed interest and only 6 participated. 49 residents were recruited (median 8 [interquartile range 7–12] per home), mean (standard deviation) age 82 (8) years, with proxy consent 41 (84%), advance directive for hospital non-admission 8 (16%) and ≥ 1 doses of COVID-19 vaccine 37 (82%). Background dietary nitrate was 50% of juice. Residents randomised to nitrate vs placebo had higher urinary nitrate levels, median 50 [18–175] v 18 [10–50] mg/L, difference 25 [0–90]. Data paucity precluded clinical between-group comparisons; the outcome distribution was as follows: no infection 32 (67%), uncomplicated infection 0, infection requiring healthcare support 11 (23%), all-cause hospitalisation 5 (10%), all-cause mortality 0. Urinary tract infections were most common. Conclusions Recruiting UK care homes during the COVID-19 pandemic was partially successful. Supplemented dietary nitrate was tolerated and elevated urinary nitrate. Together, infections, hospitalisations and deaths occurred in 33% of residents over 60 days. A larger trial is now required. Trial Registration ISRCTN51124684. Application date 7/12/2020; assignment date 13/1/2021. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink